Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
phone
Your Position: Home > Antibody > CD28 > CD8-M120b

Monoclonal Anti-Human CD28 Antibody, premium grade

GMP version GMP-MC2824 is now available for seamless transition.

Order Now

  • Source
    Monoclonal Anti-Human CD28 Antibody, premium grade (CD8-M120b) is recombinantly produced from human 293 cells (HEK293).
    It is produced under our rigorous quality control system that incorporates a comprehensive set of tests including sterility and endotoxin tests. Product performance is carefully validated and tested for compatibility for cell culture use or any other applications in the early preclinical stage.
    GMP-MC2824 is the GMP version of this CD8-M120b. These two proteins display indistinguishable performance profiles, thereby ensuring a seamless transition for end users from early preclinical stag to later clinical phases.
  • Isotype
    Mouse IgG1 | Mouse Kappa
  • Conjugate

    Unconjugated

  • Specificity
    This product is a specific antibody specifically reacts with CD28.
  • Endotoxin
    Less than 0.002 EU per μg by the LAL method / rFC method.
  • Protein A
    <5 ppm of protein tested by ELISA.
  • Host Cell Protein
    <0.5 ng/μg of protein tested by ELISA.
  • Host Cell DNA
    <0.02 ng/μg of protein tested by qPCR.
  • Purity

    >95% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Sterility
    Negative
  • Mycoplasma
    Negative
  • Formulation

    Supplied as 0.2 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Shipping

    This product is supplied and shipped with dry ice, please inquire the shipping cost.

  • Storage

    For long term storage, the product should be stored at liquid state at -70°C.

    This product is stable after storage at:

    1. 2-8°C for 12 months under sterile conditions;
    2. -70°C for 24 months.
SDS-PAGE
CD28 SDS-PAGE

Monoclonal Anti-Human CD28 Antibody, premium grade on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

SEC-MALS
CD28 MALS images

The purity of Monoclonal Anti-Human CD28 Antibody, premium grade (Cat. No. CD8-M120b) is more than 95% and the molecular weight of this protein is around 140-160 kDa verified by SEC-MALS.

Bioactivity-CELL BASE
 CD28 CELL

Monoclonal Anti-Human CD28 Antibody, premium grade (Cat. No. CD8-M120b) stimulates secretion of IL-2 by PBMC stimulated with 4 ng/mL Monoclonal Anti-Human CD3 Antibody, Mouse IgG2a (Clone: OKT3), premium grade (Cat. No. CDE-M120a). The typical EC50 for this effect is 2.03 ng/mL (QC tested).

 CD28 CELL

The cell activity of Monoclonal Anti-Human CD28 Antibody, premium grade (Cat. No. CD8-M120b) is 3.7 times better than competitor.

Bioactivity-Stability
 CD28 STABILITY

The Cell based assay shows batch-to-batch consistency between Acro's GMP and PG CD28 Antibody.

Bioactivity-ELISA
 CD28 ELISA

Immobilized Human / Cynomolgus / Rhesus macaque CD28, His Tag at 2 μg/mL (100 μL/well) can bind Monoclonal Anti-Human CD28 Antibody, premium grade (Cat. No. CD8-M120b) with a linear range of 0.098-1.563 ng/mL (QC tested).

  • Background
    T-cell-specific surface glycoprotein CD28 is also known as TP44, is a single-pass type I membrane protein which contains one Ig-like V-type (immunoglobulin-like) domain. is one of the molecules expressed on T cells that provide co-stimulatory signals, which are required for T cell activation. CD28 is the receptor for CD80 (B7.1) and CD86 (B7.2). When activated by Toll-like receptor ligands, the CD80 expression is upregulated in antigen presenting cells (APCs). The CD86 expression on antigen presenting cells is constitutive. CD28 is the only B7 receptor constitutively expressed on naive T cells.
  • Clinical and Translational Updates

Comments (0)


ETA of in-stock products: 2 business days

Price(USD) : $358.00

Price(USD) : $558.00

Price(USD) : $950.00

Price(USD) : $1400.00

Drug Candidate Licensing

more

Drug Development Status

  • Number of Launched Drugs:0 Details
  • Number of Drugs in Clinical Trials:23 Details
  • Latest Research Phase:Phase 3 Clinical

Datasheet & Documentation

New Product Launch

Questions & Comments

This web search service is supported by Google Inc.

totop